Last updated: February 16, 2026
Product Overview
NDC 00781-7156 identifies the drug Erenumab, marketed as Aimovig. It is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, approved by the FDA in May 2018 for migraine prevention in adults.
Market Landscape
Erenumab competes within the CGRP monoclonal antibody space, which includes fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti). The global migraine drugs market is projected to reach $4.2 billion by 2027, with CGRP therapies accounting for a substantial share, driven by increased diagnosis rates and preferences for targeted therapies.
Specifics:
- U.S. Prescription Volume: In 2022, approximately 2.9 million prescriptions for Erenumab were filled, representing steady growth from 2.3 million in 2020.
- Market Penetration: Erenumab holds roughly 45% of the CGRP class prescriptions in the U.S., according to IQVIA data.
- Pricing Trends: The average wholesale price (AWP) is approximately $575 per dose, with patients typically receiving one monthly injection.
Regulatory and Reimbursement Context
- Insurance Coverage: Most insurers, including Medicare and Medicaid, cover Erenumab with prior authorization. Rebates and negotiated discounts are common, reducing net prices.
- Patent Litigation and Competition: Patent challenges are ongoing, with generics or biosimilars unlikely before 2028. Patent extensions and new indications could prolong exclusivity.
Pricing Projection
- Current Pricing: The list price remains near $575 per month, $6,900 annually.
- Near-term Trends (2023-2025): Price reductions via PBMs and formulary negotiations expect to lower net prices by 10-15%. The use of copay assistance programs will keep out-of-pocket costs stable for patients.
- Long-term Outlook (2026-2030): Patent challenges, competition from biosimilars, and market saturation may reduce list prices by 20-30%. New formulations or indications could temporarily stabilize prices.
| Year |
Estimated Price (per month) |
Notes |
| 2023 |
$575 |
Current list price, with minor reductions via negotiations |
| 2024 |
$545 - $550 |
Moderate discounts through improved formulary access |
| 2025 |
$520 - $530 |
Further price compression as market matures |
| 2026 |
$460 - $480 |
Entry of biosimilars expected, potential price decline |
| 2027-2030 |
$410 - $470 |
Patent expiry, increased competition, potential price erosion |
Market Risks
- Delays or failures in gaining insurance coverage
- Introduction of biosimilars or generics
- Shifts in prescribing practices favoring oral or alternative therapies
- Changes in drug pricing regulations affecting reimbursement
Conclusions
Erenumab occupies a leading position in migraine prevention, with stable high pricing supported by unique therapeutic benefits. Price erosion is anticipated over the next five years due to patent expiration and market competition, with discounts likely to intensify. Durable exclusivity depends on patent litigation outcomes and regulatory developments.
Key Takeaways
- Erenumab (NDC 00781-7156) is a dominant CGRP migraine therapy with approximately $6,900 annual list price.
- Prescription volumes are growing, but market share faces pressure from biosimilars and competing drugs.
- Price reductions of 10-30% are expected over the next five years due to formulary negotiations and patent challenges.
- Long-term, biosimilar entry could significantly lower net prices.
- Market risks include insurance coverage barriers and emerging oral migraine treatments.
FAQs
1. How does Erenumab compare price-wise to similar therapies?
Erenumab's list price of approximately $575 per dose aligns with fremanezumab and galcanezumab, though actual net prices vary due to rebates and negotiations.
2. When can biosimilars be expected to impact the market?
Biosimilars are unlikely before 2028, contingent upon patent litigation outcomes and regulatory approvals.
3. What factors could influence Erenumab’s market share?
Introduction of new oral prophylactics, changes in reimbursement policies, and patient preferences for less invasive options.
4. How does insurance coverage impact pricing?
Most insurers cover Erenumab, but negotiated discounts and prior authorization requirements influence actual out-of-pocket costs and net revenue.
5. What is the main driver of price stability in the near term?
Rebates, patient assistance programs, and the drug’s clinical efficacy sustain demand despite high list prices.
References
[1] IQVIA. "Market Trends in Migraine Therapeutics," 2022.
[2] FDA. "Erenumab (Aimovig) Approval Summary," 2018.
[3] EvaluatePharma. "Forecast of CGRP Therapies Market," 2022.
